{"eventGroups":[{"description":"Participants with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma who met the inclusion criteria and did not meet exclusion criteria of the study were enrolled and were evaluated for the presence of BRAF V600 mutations by collecting tumor samples or performing fresh biopsies according to local standards.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":548,"seriousNumAffected":0,"seriousNumAtRisk":548,"title":"Participants With Confirmed Solid Tumors or Multiple Myeloma"}],"frequencyThreshold":"5","timeFrame":"All adverse events that occurred up to 28 days after the biopsy was performed or those adverse events that the physician considered to have causal relationship to the biopsy performed were recorded."}